Home › Urothelial (Transitional Cell) Carcinoma › Illinois
Urothelial (Transitional Cell) Carcinoma clinical trials in Illinois
21 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in Illinois.
Cities in Illinois
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- University of Illinois, Chicago
- Carle at The Riverfront, Danville
- Cancer Care Specialists of Illinois - Decatur, Decatur
- and 13 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
- Southern Illinois University, Springfield
Recruiting
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06262516Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- Hope and Healing Clinical Research LLC, Hinsdale
- Hope and Healing Clinical Research LLC, New Lenox
- Illinois Cancer Specialists, Niles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- and 12 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Northwestern University, Chicago
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- University of Chicago Medical Center ( Site 1037), Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05562830Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- City of Hope Cancer Center-Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
- Endeavor Health, Evanston
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Niles
- Research Site, Peoria
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07129993A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
- Accellacare - Deerfield, Deerfield
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- The University of Chicago Medical Center - Oncology, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07169734Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- COH Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07484022Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-012 - University of Chicago, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 24, 2025 · NCT03945162SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
RecruitingObservational study
Ages 18 to 100 · All sexes · Updated Oct 10, 2025 · NCT06310759A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
- Northwestern University, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 10, 2023 · NCT05733000From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.